The objective of this article is to review the efficacy, safety, and evidence for current use and potential future uses of immune-checkpoint inhibitors (ICIs) in the management of resectable non-small cell lung cancer (NSCLC).
Data sources
A literature review was carried out through PubMed to identify completed and ongoing clinical trials evaluating the use, efficacy, and safety of ICIs in the management of resectable NSCLC.
Data summary
To date, four phase 3 trials have emerged that have changed our treatment practice concerning the utilization of ICIs during the adjuvant and neoadjuvant settings. The IMpower010 and KEYNOTE-091 trials examined the application of adjuvant atezolizumab and pembrolizumab, respectively, following surgical resection and adjuvant chemotherapy. In the CheckMate 816 trial, the combination of nivolumab and chemotherapy as a neoadjuvant therapy received approval for patients with resectable NSCLC. Also, for patients with resectable NSCLC, the use of a pembrolizumab and chemotherapy combination as a perioperative therapy received approval based on the results of the KEYNOTE-671 trial. Apart from these trials, there are numerous phase 2 and phase 3 trials, some of which have been published while others are still in progress.
Conclusion
Despite the promising outcomes from these trials there remain several unanswered questions. In this review, we will assess clinical trials involving adjuvant, neoadjuvant, and perioperative ICIs, aiming to address the unresolved questions related to these therapeutic approaches.
SungHFerlayJSiegelRL, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin2021; 71: 209–249.
VansteenkisteJCrinòLDoomsC, et al.2nd ESMO consensus conference on lung cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol2014; 25: 1462–1474.
4.
PignonJ-PTribodetHScagliottiGV, et al.Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group. J Clin Oncol2008; 26: 3552–3559.
5.
UramotoHTanakaF. Recurrence after surgery in patients with NSCLC. Transl Lung Cancer Res2014; 3: 242–249.
6.
GoldstrawPChanskyKCrowleyJ, et al.The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol2016; 11: 39–51.
7.
Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet2014; 383: 1561–1571.
8.
LimEHarrisGPatelA, et al.Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials. J Thorac Oncol2009; 4: 1380–1388.
9.
FelipERosellRMaestreJA, et al.Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non–small-cell lung cancer. J Clin Oncol2010; 28: 3138–3145.
10.
EsfahaniKRoudaiaLBuhlaigaN, et al.A review of cancer immunotherapy: from the past, to the present, to the future. Curr Oncol2020; 27: S87–S97.
GrantMJHerbstRSGoldbergSB. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. Nat Rev Clin Oncol2021; 18: 625–644.
13.
MountziosGRemonJHendriksLEL, et al.Immune-checkpoint inhibition for resectable non-small-cell lung cancer – opportunities and challenges. Nat Rev Clin Oncol2023; 20: 664–667.
14.
MatznerPSandbankENeemanE, et al.Harnessing cancer immunotherapy during the unexploited immediate perioperative period. Nat Rev Clin Oncol2020; 17: 313–326.
15.
TangWFYeHYTangX, et al.Adjuvant immunotherapy in early-stage resectable non-small cell lung cancer: a new milestone. Front Oncol2023; 13: 1063183.
16.
VansteenkisteJWautersEReymenB, et al.Current status of immune checkpoint inhibition in early-stage NSCLC. Ann Oncol2019; 30: 1244–1253.
17.
FelipEAltorkiNZhouC, et al.Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet2021; 398: 1344–1357.
18.
FelipEAltorkiNZhouC, et al.Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial. Ann Oncol2023; 34: 907–919.
19.
O'BrienMPaz-AresLMarreaudS, et al.Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol2022; 23: 1274–1286.
20.
PetersSBesseBMarreaudS, et al.930MO PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: subgroup analysis of PEARLS/KEYNOTE-091. Ann Oncol2022; 33: S971–S972.
21.
GaronEBLuSGotoY, et al.LBA49 CANOPY-A: phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC). Ann Oncol2022; 33: S1414–S1415.
22.
ChaftJEDahlbergSEKhullarOV, et al.EA5142 adjuvant nivolumab in resected lung cancers (ANVIL). J Clin Oncol2018; 36: TPS8581–TPS8581.
23.
SandsJMMandrekarSJKozonoD, et al.Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). Immunotherapy2021; 13: 727–734.
24.
PetersSSpigelDAhnM, et al.P03.03 MERMAID-1: a phase III study of adjuvant durvalumab plus chemotherapy in resected NSCLC patients with MRD+ post-surgery. J Thorac Oncol2021; 16: S258–S259.
25.
SpigelDRPetersSAhnMJ, et al.93TiP MERMAID-2: phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD+ after curative-intent therapy. J Thorac Oncol2021; 16: S745–S746.
26.
CalvoVDomineMSullivanI, et al.A phase III clinical trial of adjuvant chemotherapy versus chemoimmunotherapy for stage IB-IIIA completely resected non-small cell lung cancer (NSCLC) patients nadim-adjuvant: new adjuvant trial of chemotherapy versus chemoimmunotherapy. J Clin Oncol2021; 39: TPS8581–TPS8581.
27.
FelipERosellRMaestreJA, et al.Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol2010; 28: 3138–3145.
28.
WuXChauYFBaiH, et al.Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers. Front Oncol2022; 12: 1099304.
29.
NiYLeiJHuangW, et al.Systematic review of the perioperative immunotherapy in patients with non-small cell lung cancer: evidence mapping and synthesis. Front Oncol2023; 13: 1092663.
30.
JunkerKLangnerKKlinkeF, et al.Grading of tumor regression in non-small cell lung cancer: morphology and prognosis. Chest2001; 120: 1584–1591.
31.
BlumenthalGMBunnPAJrChaftJE, et al.Current status and future perspectives on neoadjuvant therapy in lung cancer. J Thorac Oncol2018; 13: 1818–1831.
32.
ShuCACasconeT. What is neo? Chemoimmunotherapy in the neoadjuvant setting for resectable non-small-cell lung cancer. J Clin Oncol2021; 39: 2855–2858.
33.
JanjigianYYWolchokJDAriyanCE. Eradicating micrometastases with immune checkpoint blockade: strike while the iron is hot. Cancer Cell2021; 39: 738–742.
34.
FordePMChaftJESmithKN, et al.Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med2018; 378: 1976–1986.
35.
RosnerSReussJEZahurakM, et al.Five-year clinical outcomes after neoadjuvant nivolumab in resectable non-small cell lung cancer. Clin Cancer Res2023; 29: 705–710.
36.
GaoSLiNGaoS, et al.Neoadjuvant PD-1 inhibitor (sintilimab) in NSCLC. J Thorac Oncol2020; 15: 816–826.
37.
ZhangFGuoWZhouB, et al.Three-year follow-up of neoadjuvant programmed cell death protein-1 inhibitor (sintilimab) in NSCLC. J Thorac Oncol2022; 17: 909–920.
38.
BarJUrbanDOfekE, et al.Neoadjuvant pembrolizumab (pembro) for early stage non-small cell lung cancer (NSCLC): updated report of a phase I study, MK3475-223. J Clin Oncol2019; 37: 8534–8534.
39.
EichhornFKlotzLVKriegsmannM, et al.Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: first clinical experience. Lung Cancer2021; 153: 150–157.
40.
BarJUrbanDRedinskyI, et al.OA11.01 Neoadjuvant pembrolizumab for early stage non-small cell lung cancer. J Thorac Oncol2021; 16: S865–S866.
41.
LeeJChaftJNicholasA, et al.PS01.05 surgical and clinical outcomes with neoadjuvant atezolizumab in resectable stage IB–IIIB NSCLC: LCMC3 trial primary analysis. J Thorac Oncol2021; 16: S59–S61.
42.
ChaftJEOezkanFKrisMG, et al.Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. Nat Med2022; 28: 2155–2161.
43.
WislezMMazieresJLavoleA, et al.Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO). J Immunother Cancer2022; 10. DOI: https://doi.org/10.1136/jitc-2022-005636
44.
BesseBAdamJCozicN, et al.1215O – SC neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): results from the phase II PRINCEPS trial. Ann Oncol2020; 31: S794–S795.
45.
CasconeTWilliamWNWeissferdtA, et al.Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med2021; 27: 504–514.
46.
ReussJEAnagnostouVCottrellTR, et al.Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer. J Immunother Cancer2020; 8: e001282.
47.
CasconeTGarcía-CampeloRSpicerJ, et al.Abstract CT011: neoCOAST: open-label, randomized, phase 2, multidrug platform study of neoadjuvant durvalumab alone or combined with novel agents in patients (pts) with resectable, early-stage non-small-cell lung cancer (NSCLC). Cancer Res2022; 82: CT011–CT011.
48.
AignerCPontBDHarteminkK, et al.Surgical outcomes of patients with resectable non-small-cell lung cancer receiving neoadjuvant immunotherapy with nivolumab plus relatlimab or nivolumab: findings from the prospective, randomized, multicentric phase II study NEOpredict-lung. J Clin Oncol2023; 41: 8500–8500.
49.
AwadMMFordePMGirardN, et al.1261O neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial. Ann Oncol2023; 34: S731.
50.
FordePMSpicerJLuS, et al.Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med2022; 386: 1973–1985.
51.
Paz-AresLLuftAVicenteD, et al.Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. N Engl J Med2018; 379: 2040–2051.
52.
SocinskiMAJotteRMCappuzzoF, et al.Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med2018; 378: 2288–2301.
53.
KeppOGalluzziLMartinsI, et al.Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev2011; 30: 61–69.
54.
YangC-FJMcSherryFMayneNR, et al.Surgical outcomes after neoadjuvant chemotherapy and ipilimumab for non-small cell lung cancer. Ann Thorac Surg2018; 105: 924–929.
55.
ShuCAGainorJFAwadMM, et al.Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol2020; 21: 786–795.
56.
HenickBSGainorJFAwadMM, et al.Abstract CT217: 3-year update of neoadjuvant atezolizumab + chemotherapy in patients with resectable non-small cell lung cancer. Cancer Res2023; 83: CT217–CT217.
57.
ZhangPDaiJSunF, et al.Neoadjuvant sintilimab and chemotherapy for resectable stage IIIA non-small cell lung cancer. Ann Thorac Surg2022; 114: 949–958.
58.
ZhaoZ-RYangC-PChenS, et al.Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer. OncoImmunology2021; 10: 1996000.
59.
YanSChenJWangJ, et al.64P neoadjuvant toripalimab plus chemotherapy in patients with potentially resectable non-small cell lung cancer: a prospective, single-arm, phase II trial (renaissance study). Ann Oncol2021; 32: S1400.
60.
ZhuXSunLSongN, et al.Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial. BMC Med2022; 20: 93.
61.
HeymachJVMitsudomiTHarpoleD, et al.Design and rationale for a phase III, double-blind, placebo-controlled study of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab for the treatment of patients with resectable stages II and III non-small-cell lung cancer: the AEGEAN trial. Clin Lung Cancer2022; 23: e247–e251.
62.
LuSWuLZhangW, et al.Perioperative toripalimab + platinum-doublet chemotherapy vs chemotherapy in resectable stage II/III non-small cell lung cancer (NSCLC): interim event-free survival (EFS) analysis of the phase III neotorch study. J Clin Oncol2023; 41: 425126–425126.
63.
WakeleeHLibermanMKatoT, et al.Perioperative pembrolizumab for early-stage non–small-cell lung cancer. N Engl J Med2023; 389: 491–503.
64.
CasconeTAwadMMSpicerJD, et al.LBA1 checkmate 77T: phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC. Ann Oncol2023; 34: S1295.
65.
AkinboroODreznerNAmatyaA, et al.US food and drug administration approval summary: nivolumab plus platinum-doublet chemotherapy for the neoadjuvant treatment of patients with resectable non–small-cell lung cancer. J Clin Oncol2023; 41: 3249–3259.
66.
SpicerJFordePMProvencioM, et al.Clinical outcomes with neoadjuvant nivolumab (N) + chemotherapy (C) vs C by definitive surgery in patients (pts) with resectable NSCLC: 3-y results from the phase 3 CheckMate 816 trial. J Clin Oncol2023; 41: 8521–8521.
67.
CasconeTLeungCHWeissferdtA, et al.Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med2023; 29: 593–604.
68.
MokTSKPujolJLTsuboiM, et al.LBA4 CANOPY-N: a phase II study of canakinumab (CAN) or pembrolizumab (PEM), alone or in combination, as neoadjuvant therapy in patients (pts) with resectable stage Ib–IIIa non-small cell lung cancer (NSCLC). Ann Oncol2022; 33: S1547–S1548.
69.
ZhaoXSuYYouJ, et al.Combining antiangiogenic therapy with neoadjuvant chemotherapy increases treatment efficacy in stage IIIA (N2) non-small cell lung cancer without increasing adverse effects. Oncotarget2016; 7: 62619–62626.
70.
AokageKShimadaYYohK, et al.Pembrolizumab and ramucirumab neoadjuvant therapy for PD-L1-positive stage IB-IIIA lung cancer (EAST ENERGY). J Clin Oncol2023; 41: 8509–8509.
71.
DemariaSGoldenEBFormentiSC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol2015; 1: 1325–1332.
72.
Twyman-Saint VictorCRechAJMaityA, et al.Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature2015; 520: 373–377.
73.
HongMHAhnBKimHR, et al.FP03.02 interim analysis of neoadjuvant chemoradiotherapy and durvalumab for potentially resectable stage III non-small cell lung cancer (NSCLC). J Thorac Oncol2021; 16: S194–S195.
74.
AltorkiNKMcGrawTEBorczukAC, et al.Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncol2021; 22: 824–835.
75.
LeeBMynardNNasarA, et al.Surgical resection after neoadjuvant durvalumab and radiation is feasible and safe in non-small cell lung cancer: results from a randomized trial. J Thorac Cardiovasc Surg2023; 165: 327–334.e322.
76.
TongBCGuLWangX, et al.Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg2022; 163: 427–436.
77.
ProvencioMNadalEInsaA, et al.Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol2020; 21: 1413–1422.
78.
ProvencioMSerna-BlascoRNadalE, et al.Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non-small-cell lung cancer (NADIM phase II trial). J Clin Oncol2022; 40: 2924–2933.
79.
RothschildSIZippeliusAEbouletEI, et al.SAKK 16/14: durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small-cell lung cancer-a multicenter single-arm phase II trial. J Clin Oncol2021; 39: 2872–2880.
80.
QiuFFanJShaoM, et al.Two cycles versus three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small-cell lung cancer (neoSCORE): a randomized, single center, two-arm phase II trial. J Clin Oncol2022; 40: 8500–8500.
81.
ProvencioMNadalEGonzález-LarribaJL, et al.Perioperative nivolumab and chemotherapy in stage III non–small-cell lung cancer. N Engl J Med2023; 389: 504–513.
82.
HeymachJVHarpoleDMitsudomiT, et al.Abstract CT005: AEGEAN: a phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC. Cancer Res2023; 83: CT005–CT005.
83.
HeymachJVHarpoleDMitsudomiT, et al.Perioperative durvalumab for resectable non–small-cell lung cancer. N Engl J Med2023; 389: 1672–1684.
84.
SpicerJDGaoSLibermanM, et al.LBA56 overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC). Ann Oncol2023; 34: S1297–S1298.
85.
MautiLAFinazziTHolerL, et al.SAKK 16/18: immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC)—a multicenter phase II trial. J Clin Oncol2023; 41: 8547–8547.
86.
LemmonCAVideticGMMMurthyS, et al.A phase 1 study of concurrent neoadjuvant pembrolizumab plus chemoradiation followed by consolidation pembrolizumab in patients with resectable stage IIIA NSCLC. JTO Clin Res Rep2022; 3: 100359.
87.
GuisierFBennounaJSpiraAI, et al.NeoCOAST-2: a phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC). J Clin Oncol2023; 41: TPS8604–TPS8604.
88.
PetersSKimAWSolomonB, et al.IMpower030: phase III study evaluating neoadjuvant treatment of resectable stage II-IIIB non-small cell lung cancer (NSCLC) with atezolizumab (atezo) + chemotherapy. Ann Oncol2019; 30: ii30.
89.
SawSPLOngBHChuaKLM, et al.Revisiting neoadjuvant therapy in non-small-cell lung cancer. Lancet Oncol2021; 22: e501–e516.
90.
BetticherDCSchmitzS-FHTötschM, et al.Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non–small-cell lung cancer: a multicenter phase II trial. J Clin Oncol2003; 21: 1752–1759.
91.
ShaoMYaoJWangY, et al.Two vs three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small-cell lung cancer: neoSCORE trial. Signal Transduct Target Ther2023; 8: 46.
92.
RianoIAbualiISharmaA, et al.Role of neoadjuvant immune checkpoint inhibitors in resectable non-small cell lung cancer. Pharmaceuticals (Basel)2023; 16: 20230203.
93.
PengYLiZFuY, et al.Progress and perspectives of perioperative immunotherapy in non-small cell lung cancer. Front Oncol2023; 13: 1011810.
94.
DavisAAPatelVG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US food and drug administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer2019; 7: 278.
95.
ZhangJTLiuSYGaoW, et al.Longitudinal undetectable molecular residual disease defines potentially cured population in localized non-small cell lung cancer. Cancer Discov2022; 12: 1690–1701.
96.
StricklerJHHanksBAKhasrawM. Tumor mutational burden as a predictor of immunotherapy response: is more always better?Clin Cancer Res2021; 27: 1236–1241.
97.
ZhangYZhangZ. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol2020; 17: 807–821.
98.
Laza-BriviescaRCruz-BermudezACasarrubiosM, et al.P2.04-10 biomarkers of pathological response on neo-adjuvant chemo-immunotherapy treatment for resectable stage IIIA NSCLC patients. J Thorac Oncol2019; 14: S711.
99.
HellmannMDChaftJEWilliamWNJr, et al.Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol2014; 15: e42–e50.
100.
LiaoWYChenJHWuM, et al.Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer. Clin Lung Cancer2013; 14: 418–424.
101.
MouilletGMonnetEMilleronB, et al.Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials. J Thorac Oncol2012; 7: 841–849.
102.
ShinadaKMurakamiS. Neoadjuvant PD-1 blockade in non-small cell lung cancer: current perspectives and moving forward. Onco Targets Ther2023; 16: 99–108.
103.
PataerAKalhorNCorreaAM, et al.Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J Thorac Oncol2012; 7: 825–832.
104.
WilliamWNPataerAKalhorN, et al.Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy. J Thorac Oncol2013; 8: 222–228.
105.
Provencio-PullaMSpicerJTaubeJM, et al.Neoadjuvant nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) versus chemo for resectable (IB–IIIA) non-small cell lung cancer (NSCLC): association of pathological regression with event-free survival (EFS) in CheckMate 816. J Clin Oncol2022; 40: LBA8511–LBA8511.
